Development of a gas chromatographic/mass spectrometric method to quantify R(–)-apomorphine, R(–)-apocodeine and R(–)-norapomorphine in human plasma and urine
Version of Record online: 14 NOV 2005
Copyright © 2005 John Wiley & Sons, Ltd.
Journal of Mass Spectrometry
Volume 40, Issue 12, pages 1521–1525, December 2005
How to Cite
Libert, F., Coudoré, F., Richard, D., Durif, F. and Eschalier, A. (2005), Development of a gas chromatographic/mass spectrometric method to quantify R(–)-apomorphine, R(–)-apocodeine and R(–)-norapomorphine in human plasma and urine. J. Mass Spectrom., 40: 1521–1525. doi: 10.1002/jms.939
- Issue online: 30 NOV 2005
- Version of Record online: 14 NOV 2005
- Manuscript Accepted: 20 SEP 2005
- Manuscript Received: 12 AUG 2005
A method was developed and validated for the analysis of R(−)-apomorphine, (R−)-apocodeine and R(−)-norapomorphine in human plasma and urine with N-propylnorapomorphine as internal standard using gas chromatography/mass spectrometry (GC/MS) and single-ion monitoring after a single liquid–liquid extraction and silylation of compounds. The quantification limits were 1 ng/ml for apomorphine and apocodeine and 25 ng/ml for norapomorphine. Calibration curves were linear, within the range 1–100 ng/ml. Variation in intraday and interday precision was below 10%. This method was applied to study apomorphine bioavailability in nine patients with Parkinson's disease before and after coadministration of a catechol-O-methyl transferase inhibitor. Copyright © 2005 John Wiley & Sons, Ltd.